Impel Pharmaceuticals to Present Data on Trudhesa® Nasal Spray for Treatment of Acute Migraine at 2023 American Academy of Neurology Annual Meeting

Rhea-AI Summary

Impel Pharmaceuticals Highlights Trudhesa Presentations

On April 11, 2023, Impel Pharmaceuticals (NASDAQ: IMPL) announced that four abstracts featuring its Trudhesa^® nasal spray will be presented at the American Academy of Neurology Annual Meeting in Boston, running from April 22-27, 2023. The presentations will cover topics such as the management of status migrainosus, drug-drug interactions with gepants, and the safety and efficacy of Trudhesa in conjunction with other treatments. Key presentation times include April 26 at 11:45 a.m. and 5:30 p.m. ET, and April 27 at 8:00 a.m. and 11:45 a.m. ET. This meeting is significant for Impel as it showcases ongoing efforts to address unmet medical needs in migraine treatment, particularly following Trudhesa's FDA approval for acute migraine treatment in adults.

Highlights Include Multiple Presentations Addressing Safety and Efficacy of Trudhesa

SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, announced today that four Trudhesa^® (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) abstracts have been selected to be presented at the upcoming American Academy of Neurology (AAN) Annual Meeting taking place in Boston, MA, April 22-27, 2023.

The Trudhesa posters to be presented are as follows:

• A Cross-Sectional Survey of Prevailing Opinions from Headache Specialists Regarding Status Migrainosus Management; (Poster 12-001; Session 11)
  • Presentation Time: Wednesday, April 26, 2023, 11:45 a.m. ET
  • Clinical Collaborators: Jennifer Robblee, M.D., Barrow Neurological Institute, Phoenix, AZ
• Assessment of the Potential for Drug–Drug Interactions Between INP104 and Gepants for Migraine Management Using a Model-based Approach (Poster 12-008; Session 12)
  • Clinical Collaborators: Sutapa Ray, PhD., Impel Pharmaceuticals, Seattle, WA
  • Presentation Time: Wednesday, April 26, 2023, 5:30 p.m. ET
• Safety and Efficacy of Concomitant Erenumab and INP104 Use from the Phase 3 STOP 301 Study in Migraine Patients (Poster 12-002; Session 13)
  • Presentation Time: Thursday, April 27, 2023, 8:00 a.m. ET
  • Clinical Collaborators: Zubair Ahmed, M.D., Cleveland Clinic, Cleveland, OH
• Safety of Concomitant Triptan and INP104 Use from the Phase 3 STOP 301 Study in Migraine Patients (Poster 12-011; Session 14)
  • Presentation Time: Thursday, April 27, 2023, 11:45 a.m. ET
  • Clinical Collaborators: Alexander Feoktistov, M.D., Synergy Integrative Headache Center, Northfield, IL

The full abstracts can be found on the AAN website.

About Impel Pharmaceuticals
Impel Pharmaceuticals is a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs. Impel offers treatments that pair its proprietary POD^® technology with well-established therapeutics. In September 2021, Impel received U.S. FDA approval for its first product, Trudhesa^® nasal spray, which is approved in the U.S. for the acute treatment of migraine with or without aura in adults. In addition to Trudhesa, the Company continues to address patient needs via licensing and partnerships.

About Impel’s Precision Olfactory Delivery (POD^®) Technology:
Impel’s proprietary POD^® technology is able to deliver a range of therapeutic molecules and formulations into the vascular-rich upper nasal space, believed to be a gateway for unlocking the previously unrealized full potential of these molecules. By delivering predictable doses of drug directly to the upper nasal space, Impel’s precision performance technology has the goal of enabling increased and consistent absorption of drug, overriding the high variability associated with other nasal delivery systems, yet without the need for an injection. While an ideal target for drug administration, to date no technology has been able to consistently deliver drugs to the upper nasal space. By utilizing this route of administration, Impel Pharmaceuticals has been able to demonstrate blood concentration levels for its investigational therapies that are comparable to intramuscular (IM) administration and can even reach intravenous (IV)-like systemic levels quickly. Importantly, the POD technology offers propellant-enabled delivery of dry powder and liquid formulations that eliminates the need for coordination of breathing, allowing for self- or caregiver-administration in a manner that may improve patient outcome, comfort, and potentially, compliance.

About Trudhesa^®
Indication
Trudhesa^® is used to treat an active migraine headache with or without aura in adults. Do not use Trudhesa to prevent migraine when you have no symptoms. It is not known if Trudhesa is safe and effective in children.

Important Safety Information

Serious or potentially life-threatening reductions in blood flow to the brain or extremities due to interactions between dihydroergotamine (the active ingredient in Trudhesa) and strong CYP3A4 inhibitors (such as protease inhibitors and macrolide antibiotics) have been reported rarely. As a result, these medications should not be taken together.

Do not use Trudhesa if you:

• Have any disease affecting your heart, arteries, or blood circulation.
• Are taking certain anti-HIV medications known as protease inhibitors (such as ritonavir or nelfinavir).
• Are taking a macrolide antibiotic such as clarithromycin or erythromycin.
• Are taking certain antifungals such as ketoconazole or itraconazole.
• Have taken certain medications such as triptans or ergot-type medications for the treatment or prevention of migraine within the last 24 hours.
• Have taken any medications that constrict your blood vessels or raise your blood pressure.
• Have severe liver or kidney disease.
• Are allergic to ergotamine or dihydroergotamine.

Before taking Trudhesa, tell your doctor if:

• You have high blood pressure, chest pain, shortness of breath, heart disease; or risk factors for heart disease (such as high blood pressure, high cholesterol, obesity, diabetes, smoking, strong family history of heart disease or you are postmenopausal, or male over 40); or problems with blood circulation in your arms, legs, fingers, or toes.
• You have or had any disease of the liver or kidney.
• You are taking any prescription or over-the-counter medications, including vitamins or herbal supplements.
• You are pregnant, planning to become pregnant or are nursing, or have ever stopped medication due to an allergy or bad reaction.
• This headache is different from your usual migraine attacks.
  

The use of Trudhesa should not exceed dosing guidelines and should not be used on a daily basis. Serious cardiac (heart) events, including some that have been fatal, have occurred following the use of dihydroergotamine mesylate, particularly with dihydroergotamine for injection, but are extremely rare.

You may experience some nasal congestion or irritation, altered sense of taste, sore throat, nausea, vomiting, dizziness, and fatigue after using Trudhesa.
Contact your doctor immediately if you experience:

• Numbness or tingling in your fingers and toes
• Severe tightness, pain, pressure, heaviness, or discomfort in your chest
• Muscle pain or cramps in your arms or legs
• Cold feeling or color changes in one or both legs or feet
• Sudden weakness
• Slurred speech
• Swelling or itching
  

The risk information provided here is not comprehensive. To learn more, talk about Trudhesa with your healthcare provider or pharmacist. The FDA-approved product labeling can be found at www.Trudhesa.com or 1-800-555-DRUG. You can also call 1-833-TRUDHESA (1-833-878-3437) for additional information.

Cautionary Note on Forward-Looking Statements
This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, the potential clinical benefits of Trudhesa^®, the market opportunities of Trudhesa within the migraine market, the speed of uptake and market growth of Trudhesa, the effectiveness of the Trudhesa sales force, the timing of announcements of clinical results and clinical development activities of Impel’s product candidates, and Impel’s cash runway. Forward-looking statements can be identified by words such as: “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect” or the negative or plural of these words or similar expressions. These statements are subject to numerous risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including but not limited to, Impel’s ability to maintain regulatory approval of Trudhesa, its ability to execute its commercialization strategy for Trudhesa, its ability to develop, manufacture and commercialize its other product candidates including plans for future development of its POD^® devices and plans to address additional indications for which Impel may pursue regulatory approval, whether results of preclinical studies or clinical trials will be indicative of the results of future trials, and the effects of COVID-19 on its clinical programs and business operations. Many of these risks are described in greater detail in Impel’s filings with the Securities and Exchange Commission. Any forward-looking statements in this press release speak only as of the date of this press release. Impel assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Impel, POD, Trudhesa and the Impel logo are registered trademarks of Impel Pharmaceuticals Inc. To learn more about Impel Pharmaceuticals, please visit our website at https://impelpharma.com.

Contact:
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 201-723-5805
Email: mweible@elixirhealthpr.com

FAQ

What are the presentation details for Impel Pharmaceuticals' Trudhesa at the AAN Annual Meeting?

Impel Pharmaceuticals will present four abstracts on Trudhesa at the AAN Annual Meeting in Boston from April 22-27, 2023. Key presentations occur on April 26 at 11:45 a.m. and 5:30 p.m. ET, and April 27 at 8:00 a.m. and 11:45 a.m. ET.

What is Trudhesa and what conditions does it treat?

Trudhesa^® is a nasal spray approved for the acute treatment of migraine with or without aura in adults, not for prevention.

When was Trudhesa approved by the FDA?

Trudhesa received FDA approval in September 2021.

What topics will be presented regarding Trudhesa at the American Academy of Neurology meeting?

Topics include management strategies for status migrainosus and assessments of drug interactions involving Trudhesa.

What are the potential benefits of using Trudhesa for migraine treatment?

Trudhesa aims to provide effective migraine relief through a novel nasal delivery system that facilitates quick absorption.